Batch Release

Batch Release in Saudi Arabia: The Qualified Person's Role

In Saudi Arabia, a Qualified Person (QP) certifies each finished batch before it can be sold, supplied or exported, and that certification is the quality release. It is not QA’s approval of the record, and it is not the warehouse moving stock. Annex 16 of the SFDA Guide to Good Manufacturing Practice, version 4.4, says each site making product in the Kingdom must have at least one QP, and that certification can only be performed by a QP of the manufacturer or importer named in the marketing authorisation. What the QP must be assured of before signing is long, and most of it depends on records the QP did not write.

The plants that cope with this are the ones where the QP’s checklist is a document the quality unit prepared days earlier, not something assembled the night the batch is due to ship. This article covers who qualifies, what that checklist has to contain, what changes for imported products, and where review by exception fits. For the mechanics of review by exception itself, see our article on electronic batch record review by exception; we do not repeat it here.

Who May Certify, and What SFDA Calls Them

SFDA’s guide follows the EU GMP structure, and it carries its own Annex 16, titled “Qualified Person and Batch Release”. Its glossary defines the Qualified Person as “the person defined in Law of Facilities and Pharmaceutical Preparations”. The qualification requirements therefore live in that law and its implementing rules, which Annex 16 does not reproduce, so take them from the SFDA rather than from a summary. Chapter 2, paragraph 2.6(b) says QPs must meet the qualification requirements laid down in national legislation and be permanently and continuously at the disposal of the manufacturing authorisation holder.

A note on titles. The guide uses “Qualified Person” throughout Chapters 1, 2 and 4 and Annex 16. “Authorised Person” is the term in its advanced therapy medicinal products annex (Annex 2A), where the Authorised Person certifies ATMP batches and holds ultimate responsibility for that certification. For a conventional plant, appoint a QP.

Three structural points that surprise people:

  • The QP does not have to be a separate post. Paragraph 2.5 says senior management appoints the head of Production, the head of Quality Control and, if at least one of them is not responsible for release, the QP designated for the purpose. The heads of Production and Quality Control must be independent of each other.
  • Certification cannot be handed on. Paragraph 2.6(c) allows delegation of a QP’s responsibilities only to other QPs.
  • Several QPs can share one batch. Where a batch passes through more than one site, paragraph 1.4 lets a QP at a partial-manufacturing site confirm the steps done there, and the certifying QP may rely on those confirmations, provided the sharing is defined in a document formally agreed by all parties, including who assesses the impact of any deviation (1.4.3). Appendix I gives the form of confirmation and Appendix II the content of the batch certificate.

SFDA has been a PIC/S participating authority since 1 July 2023, and the Annex 16 text reads like the PIC/S-aligned EU annex. The numbering is not identical to the EU annex, however, so cite SFDA’s clause numbers in SOPs and inspection answers, not the EU ones.

What Must Be Reviewed Before Release

Annex 16 splits the QP’s duties in two. Paragraph 1.6 lists what the QP must personally ensure: that certification is permitted under the manufacturing authorisation, that national legislation is complied with, and that the certification is recorded in a register or equivalent document. Paragraph 1.7 then lists nineteen points the QP is responsible for securing, and says these tasks “may be delegated to appropriately trained personnel or third parties”, with the QP holding ongoing assurance that reliance on the quality system is well founded. The ones that translate into pre-release review work:

Annex 16 pointWhat it asksWhere the evidence usually sits
1.7.10All records complete and endorsed by appropriate personnel; all required in-process controls and checks madeBatch record, in-process control results
1.7.11Manufacturing and testing processes remain in the validated state; personnel trained and qualifiedValidation status, training matrix
1.7.12Finished product QC data comply with the finished product specification in the MALaboratory results, CoA
1.7.13Post-marketing commitments addressed; ongoing stability data continues to support certificationStability programme, commitment tracker
1.7.14Impact of any change to manufacturing or testing evaluated and additional checks completeChange control records
1.7.15All investigations on the batch, including OOS and OOT, complete enough to support certificationDeviation and OOS files
1.7.16Ongoing complaints, investigations or recalls do not negate certificationComplaint and recall log
1.7.2–1.7.4Supply chain documented; audits of manufacturing, testing and active substance sites carried out and reports available; all sites compliant with the MASupplier and contract-site audit files
1.7.17–18Technical agreements in place; self-inspection programme active and currentQuality agreements, self-inspection schedule

The batch record, deviations, QC results and change control that a QA reviewer reads are the visible part. The less visible items, 1.7.2 to 1.7.4, 1.7.13 and 1.7.18, are not batch-specific at all. They are standing conditions of the quality system, and the QP has to be able to say they were true on the day. We recommend a one-page pre-certification summary prepared by QA per batch, plus a quarterly statement from the QP’s own office on the standing items. That keeps a QP from re-deriving the supply chain every night. For the stability side of 1.7.13, see our guide to stability testing for Saudi Arabia and the GCC.

The main chapters tell the same story from the other side. Paragraph 1.9(vi) says product assessment “includes a review and evaluation of relevant production documentation and an assessment of deviations from specified procedures”, and paragraph 1.9(vii) that no batch is released before certification by a QP. Paragraph 4.27 requires written release and rejection procedures, “in particular for the certification for sale of the finished product by the Qualified Person(s)”, with all records available to the QP.

Imported Products and Testing on Import

For product made outside the Kingdom, Annex 16 paragraph 1.5 says physical importation and certification are the final stages of manufacture, and that section 1 applies to every product released to the Saudi market “irrespective of the complexity of the supply chain”. The testing rule is the one to know: unless an MRA or similar agreement exists between the Kingdom and the exporting country, the certifying QP must ensure the batch has had a full qualitative analysis, a quantitative analysis of at least all the active substances and all other tests necessary to ensure quality in line with the MA (1.5.4).

The guide does not use the term “parallel testing”. What it does document is how sampling may be organised, and that is the part inspectors probe:

  • Where samples are taken. After arrival in the Kingdom, or at the third-country manufacturing site, under a technically justified approach in the quality system, with sampling responsibilities in a written agreement (1.5.5).
  • If sampled abroad, a formal quality risk management process is required: an audit of the sampling activity and of transport, a comparative study showing the third-country samples represent the imported batch, and provision for random periodic analysis of samples taken after importation to justify continued reliance (1.5.6). An unexpected or confirmed out-of-specification result is treated as a potential quality defect and notified to the supervisory authority for the certifying site.
  • One bulk, several finished batches. The QPs certifying later batches may base their decision on QC testing of the first imported finished batch if justified, with documented verification of storage, transport, tamper-evidence, identification and sample representativeness (1.5.7).

Do not confuse this with parallel importation. Paragraph 1.9 covers repackaging of a batch that has already been released, a different case entirely, where the QP of the repackager certifies that the repackaging complied with its authorisation and GMP.

Certifying When Something Went Wrong

Section 3 of Annex 16 lets a QP consider certifying a batch despite an unexpected deviation, but only where the registered specifications are met, the deviation has been thoroughly investigated and the root cause corrected. It also requires a quality risk management assessment that evaluates the potential impact on quality, safety or efficacy and concludes the impact is negligible, and a decision on whether the batch joins the ongoing stability programme. Where responsibility is shared between QPs, the certifier must be aware of deviations at the other sites. The annex also warns that the deviation may require a variation to the marketing authorisation for continued manufacture.

How Review by Exception Changes the Work

It moves the reading, not the responsibility. With a validated electronic batch record that tests values against limits as they are entered, QA no longer reads every page. It reads the critical and major exceptions, the linked deviations, the laboratory results and the audit-trail review. For the QP that has one practical consequence. Point 1.7.10 asks the QP to be satisfied the records are complete and endorsed. If the review path was by exception, the QP needs to be able to see that it was, and that the product was eligible for it. That is a line on the pre-certification summary, not a new duty on the QP.

The failure we would watch for is a QP who signs on the strength of a clean exception list without knowing how the exception rules were set. A short list means either a stable process or loose thresholds. The QP should ask QA which, and be shown the evidence. Annex 16 is explicit that the QP can rely on the pharmaceutical quality system only while having “on-going assurance that this reliance is well founded”.

QA Approval First, QP Certification Second

Annex 16 describes three stages: checking of manufacture and testing against release procedures, certification by the QP, then transfer to saleable stock. Paragraph 4.1 says batches are released for sale or supply “only after certification by a QP” and that until then the batch stays at the manufacturing site or moves under quarantine to an approved site. Paragraph 4.2 asks for safeguards so uncertified batches do not reach saleable stock, physical (segregation, labelling) or electronic (validated computerised systems).

Our position, and the one we build to, is that the first stage ends in a recorded QA approval and the QP certifies after it, as a separate act by a named person. Combining the two in one signature hides who judged the record and who judged the compliance with the authorisation. Annex 11 points the same way: section 15 of SFDA’s Annex 11 says that where a computerised system records certification and release, it “should allow only Qualified Persons to certify”, should identify and record the person certifying, and this should be done with an electronic signature. Our note on SFDA GMP and Annex 11 covers the rest of that annex.

In Software

In Corpex-EBR, electronic batch records for SFDA-regulated plants are built on that sequence. The QA reviewer role can record the release disposition, and the release is refused while blocking conditions remain: blocking exceptions, open deviations, missing signatures, laboratory blockers, an incomplete audit-trail review or outstanding steps. Certification is a separate step that only the Qualified Person role can perform, and it is refused until QA has released the batch. For a high-criticality batch whose audit-trail review recorded findings, the QP must acknowledge those findings before certifying. Both the disposition and the certification carry an electronic signature bound to the record. Whether your site’s procedures, validation and QP appointment satisfy the SFDA is for you and your inspector; the software enforces the order, it does not appoint the QP.

Sources

All documents read on 16 November 2026. SFDA GMP Guide version 4.4 (document control date 21 May 2026):

  • SFDA Guide to Good Manufacturing Practice for Medicinal Products, version 4.4: sfda.gov.sa. Chapter 1 (1.9), Chapter 2 (2.5, 2.6), Chapter 4 (4.11, 4.27), Annex 11 (section 15) and Annex 16, including paragraphs 1.1 to 1.10, section 3, section 4 and Appendices I and II.

Frequently Asked Questions

Who can certify a batch in Saudi Arabia?

Under Annex 16 of the SFDA Guide to Good Manufacturing Practice (version 4.4), a Qualified Person certifies each finished product batch before it is released for sale, supply or export. Certification can only be performed by a QP of the manufacturer or importer described in the marketing authorisation, and each manufacturing site in Saudi Arabia must have at least one QP.

Does the SFDA use the title Authorised Person or Qualified Person?

The main text of Annex 16 and the main chapters use Qualified Person (QP). The term Authorised Person is used in the SFDA guide's advanced therapy medicinal products annex (Annex 2A) for the person who certifies ATMP batches. For a conventional medicinal product plant, the role you appoint is the QP.

Can the QP delegate certification?

No, not the certification itself. Chapter 2, paragraph 2.6(c) allows a QP's responsibilities to be delegated only to other Qualified Persons. Annex 16 paragraph 1.7 does allow the supporting tasks, points 1.7.1 to 1.7.19, to be delegated to appropriately trained personnel or third parties, provided the QP has ongoing assurance that relying on them is well founded.

Can a batch be certified when there was an unexpected deviation?

It can be, if registered specifications are met, the deviation has been thoroughly investigated and its root cause corrected, and a quality risk management assessment concludes that the impact on quality, safety or efficacy is negligible. Annex 16 section 3 also asks you to consider whether the batch belongs in the ongoing stability programme.

Does review by exception change who releases a batch?

No. Review by exception changes how the batch record is reviewed before release. The QP still certifies, and Annex 16 still makes the QP responsible for confirming that all records are complete and endorsed by appropriate personnel and that investigations are complete enough to support certification.

How long is the QP certification record kept?

Annex 16 paragraph 1.10 says the certification register must remain at the disposal of the competent authority for at least five years. Chapter 4, paragraph 4.11 sets batch documentation retention at one year after batch expiry or at least five years after QP certification, whichever is longer.

CORPEX Informatics

Enterprise software solutions for pharmaceutical, food, chemical, and manufacturing industries. Headquartered in Egypt, serving regulated industries across the MENA region since 2006.

Want QA approval and QP certification kept as separate steps?

See how Corpex-EBR refuses QP certification until QA has released the batch, and limits the certifying signature to the Qualified Person role.

Explore Corpex-EBR for Saudi Arabia